Efficacy and Tolerability of 0.2% Thiamidol Cream for Facial Hyperpigmentation: A Randomized, Double-Blind, and Vehicle-Controlled Study.

Summary

In the largest randomized double-blind vehicle-controlled trial of Thiamidol to date (n=200), 0.2% Thiamidol significantly outperformed vehicle in reducing mMASI scores at weeks 4, 8, and 12, with good tolerability. Physician global assessments favored Thiamidol, while patient-reported outcomes and digital color analysis did not significantly differ.

Key Findings

• Thiamidol achieved greater mMASI reductions than vehicle at weeks 4, 8, and 12 (11.8% vs 5.4%; 27.9% vs 13.6%; 36.1% vs 16.1%; all P<0.001).
• Physician global assessments showed slight to moderate improvement with Thiamidol at weeks 8 and 12; patient global assessments and digital color analysis showed no significant between-group differences.
• No significant adverse events; no significant improvements over vehicle for freckles or solar lentigines.

Clinical Implications

0.2% Thiamidol can be considered as a safe, effective topical option for facial hyperpigmentation (e.g., melasma features), with counseling that patient-perceived and digital color changes may lag physician-assessed improvements and that freckles/lentigines may not respond.

Limitations

• Discordance between physician assessments and patient/digital measures; limited to 12-week duration without long-term durability data.
• Population and pigmentation subtypes (e.g., freckles/lentigines) showed limited response; generalizability to diverse skin types requires further study.

Future Directions

Longer-term randomized studies across Fitzpatrick skin types, inclusion of quality-of-life endpoints, and head-to-head comparisons with standard depigmenting agents.